As immune-excluded and immune-desert STAMP tumours exhibited an upregulation in the TGFβ pathway (Fig. 2b) and a combination of TGFβ and PD-L1 inhibition has previously shown anti-tumour efficacy in mice11,25, we examined the effects of these agents in STAMP (Fig. 4a). The gene discussed is CD274; the disease is neoplasm.